drugset / Trial / NCT04090021
Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to investigate the efficacy of a 7-day genotypic resistance-guided triple therapy, compared with empirical concomitant therapy, for first-line eradication of H. pylori.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2020-02-28
- Completion
- 2020-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Levofloxacin | Small molecule | 500 mg | — |
| Comparator | Metronidazole | Small molecule | 500 mg | — |
| Subject | Rifabutin | Small molecule | 150 mg | — |
| Background | Amoxicillin | Other / unclassified | 1000 mg | — |
| Background | Esomeprazole | Small molecule | 40 mg | — |